Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adefovir + tenofovir
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Combination of adefovir and tenofovir, both nucleotide analogs that inhibit viral DNA polymerase and reverse transcriptase. This combination is contraindicated and should not be used together due to overlapping mechanisms of action and increased risk of kidney damage. Both drugs individually are used to treat chronic hepatitis B virus (HBV) infection, with tenofovir also being used for HIV treatment.
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptasePOLA1 (DNA polymerase alpha)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on adefovir + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adefovir + tenofovir.